Shenzhen Salubris Pharmaceuticals : Innovative-product growth lifted 9M revenue 15.47% as net income rose 10.93%Quartr·Oct 26, 2026 at 07:51 AM002294-0.44%
Salubris Refiles For Hong Kong IPO As Generics Lose Steambenzinga_article·Sep 10, 2026 at 05:14 PM002294-0.44%
Chinese Pharma Companies Plan Hong Kong ListingsMorningStar·Sep 4, 2026 at 02:08 AM01548-4.59%002294-0.44%
Salubris: Net profit of RMB 215.6 million in the third quarterZhitong·Oct 27, 2025 at 10:47 AM002294-0.44%
Salubris SAL0137 drug clinical trial application acceptedZhitong·Oct 15, 2025 at 09:33 AM002294-0.44%
Innovative drug concept experiences a surge, CCHT rises over 8%Zhitong·Oct 10, 2025 at 02:05 AM688331-2.49%09995-3.82%
Salubris: The clinical trial application for the drug SAL0140 has been acceptedZhitong·Sep 29, 2025 at 09:34 AM002294-0.44%
Salubris: The application for listing of Tislelizumab injection has been acceptedZhitong·Sep 19, 2025 at 10:59 AM002294-0.44%
Salubris: Ennalapril (Enalapril Tablets) new indication approved for drug registration certificateZhitong·Sep 5, 2025 at 11:27 AM002294-0.44%
Salubris: SAL0139 drug clinical trial application acceptedZhitong·Sep 5, 2025 at 11:24 AM002294-0.44%
Innovative drug concept stocks are repeatedly active, Chimin hits the daily limitZhitong·Sep 4, 2025 at 01:41 AM688356-5.81%688658-4.02%
Salubris: The clinical trial application for the self-developed innovative small molecule drug SAL0140 tablets has been acceptedZhitong·Aug 28, 2025 at 08:13 AM002294-0.44%
Salubris released its performance for the first half of the year, with a net profit attributable to the parent company of 365 million yuan, an increase of 6.10%Zhitong·Aug 19, 2025 at 10:43 AM002294-0.44%
Salubris: YOLT-101 receives implied consent for clinical trialsZhitong·Jul 14, 2025 at 08:17 AM002294-0.44%
Salubris: Aliskiren Indapamide Sustained-Release Tablets Obtained Drug Registration CertificateZhitong·Jun 4, 2025 at 09:56 AM002294-0.44%
